Navigation Links
Questions Over Value of Glucose Monitoring for Non-insulin Using Diabetes Patients

A new study published on bmj.com today (Tuesday 26 June) questions the value of blood glucose monitoring among patients with well-controlled, non-insulin dependent (type 2) diabetes.

The research, being presented today at the American Diabetes Association Conference, suggests that current guidelines for self-monitoring among these patients should be reviewed.

Non-insulin dependent (type 2) diabetes usually develops in people over 40, especially when the person is overweight. In most cases, insulin injections are not needed. Instead, a combination of dietary measures, weight reduction, and oral medication controls the condition.

Self monitoring for type 2 diabetes is costly, but many doctors believe that it helps to control blood glucose levels and it is commonly recommended. Although some studies have suggested benefits, evidence of effectiveness is still inconclusive.

So Dr Andrew Farmer and colleagues set out to test whether self-monitoring can improve blood glucose control in non-insulin using patients compared with standard care.

They identified 453 non-insulin using type 2 diabetes patients from 48 general practices.

Patients were randomly assigned to one of three groups. The control group received standard care with three-monthly HbA1c measurements by a health professional (a measure of the amount of glucose attached to red blood cells).

The second group was given a meter with advice to contact their clinician for interpretation of results (less intensive self-monitoring), while the third group was given a meter and trained to interpret the readings and apply the results (more-intensive self monitoring).

At 12 months, there was no difference in HbA1c between the groups. There was also no evidence that intensity of monitoring was related to improvements in glucose control.

This trial provides no convincing evidence of an effect of blood
'"/>




Page: 1 2

Related medicine news :

1. New Study Questions Cannibalism As A Worldwide Selective Force
2. GAO Investigation Questions Validity of DNA Testing Kits
3. African-Americans Pose Less Questions To Treating Doctors
4. Study Of Twins May Solve Aging Questions
5. Research Questions Use of Sleep Meds for Patients with Apnea
6. A Study Questions the Effectiveness of High Speed Colonoscopies
7. NYC Mayor Raises Questions About Male Circumcision as HIV Prevention Method
8. NASA Gets Ready To Address Tough Questions
9. Ask Right Questions and Save Country from Further Healthcare Crisis: Michael Moore
10. NASA Gets Ready To Address Tough Questions
11. Questions Over Drugs to Prevent Heart Complications During Surgery
Post Your Comments:
(Date:5/16/2008)... HAE: TSX, MONTREAL...ation,(TSX:HAE), a specialty bio-therapeutics comp...rcialization, announced today that its Chairman of...li, will present at the,upcoming Rodman & Renshaw ..., May 20, 2008 in the Zephyr Room at Le Meridien B...
(Date:5/16/2008)... SAO PAULO, Brazil, May 16 /PRNewswire-FirstCall/ ...rs: TEMP3.SA; Bloomberg: TEMP3 BZ), a leading,prov... benefit plans and,specialized assistance services...r of 2008. The operating and financial information...d, is presented in Brazilian Reais and in,accordan...
(Date:5/15/2008)...PHILADELPHIA) Combining natural organic atoms wit...ute have developed a new type of enzyme inhibitor ...ys a key role in cancer development. , Based on...es the way for developing new ways to treat cancer...leads to uncontrolled tumor growth. , Details of...
(Date:5/15/2008)... HARBIN, China, May 15 /Xinhua-PRNewswire-FirstCal...tin Board: CYXI) ("China Yingxia" or "the,Company"...y engaged in the,development, manufacture and dist...plements, and personal care products in the People...inancial results for the first,quarter ended March...
Breaking Medicine News(10 mins):Health News:Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Novel enzyme inhibitor paves way for new cancer drug 2Health News:Novel enzyme inhibitor paves way for new cancer drug 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9
... - how beneficial traits accumulate in natural pop...he past, two theories have addressed this problem....t confer a cost to their bearer can become common ...y "hitch a ride" with fitter genes that are being ...
...encourage patients with sexually transmitted infec...nd, in some cases, provide home testing kits or dr...dy on bmj.com. Partner notification is an importa...lly transmitted infections, but the stigma attache...
... developed a Vitamin D pill that could give a long...ge of prostrate cancer when given along with chemo...y US drug company Novacea lived for an average of ...ing chemotherapy drug taxotere alone, reported the...
...why we shed tears. But exactly what our tears are ... new study sheds some light on the complex design ...ll tear film, which is made up of three distinct, ... layer – what we normally think of as tears when w...
Other Medicine News:Health News:Study Explains How Costly Traits Evolve 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3
(Date:5/15/2008)... France, May 15 /- Cerenis,Therapeuti...ompany,developing HDL-related compounds for the tr...today announced that it has completed a Phase I,cl...d product candidates.,CER-002 is a peroxisome prol...agonist in development for the treatment of cardio...
(Date:5/15/2008)... CenterWatch, a publishing and,information service...l,trials, finds that investigative sites are requi...) systems. More than 75% of respondents to a recen...trained on three or more,EDC systems. In addition,...eir EDC training had improved., State of the Clin...
(Date:5/15/2008)...wire-FirstCall/ -- Novavax, Inc. (Nasdaq:,NVAX) to...the Phase I/IIa,study of its pandemic influenza va...cts. Favorable interim results from the first phas...70 healthy adult volunteers, were,reported in Dece... vaccine,is well tolerated and immunogenic at the ...
(Date:5/15/2008)... Plan Positions Blue Cross Blue Shield of Mic...rt from HealthLeaders-Inter...ealthLeaders-InterStudy, the,leading provider of m...he,economy continues to stagnate in Michigan, Blue...uipped of all of its competitors to weather the,ec...
Breaking Medicine Technology:Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 3Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 1Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 5Phlo Reports Sharp Revenue Increase 3441 1Phlo Reports Sharp Revenue Increase 3441 2Cancer Cure Coalition Proposes Major Changes at the FDA 1404 1Cancer Cure Coalition Proposes Major Changes at the FDA 1404 2Cancer Cure Coalition Proposes Major Changes at the FDA 1404 3Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 1Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 2Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 3Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 4
The proven daily wear spherical soft contact lens.
Surevue brand contact lenses deliver exceptional overall performance in a contact lens since they're easy to use and offer great comfort.
An easy-to-fit high water content spherical soft lens manufactured using cast molding technology, and designed for use in the correction of myopia on a daily wear or extended wear basis.
The Naugle uses reflection mirrors to measure the position of the globe accurately, even after tumor removal or thyroid decompression. It delivers fast, reproducible results. The Naugle is easy to ha
Medicine Products: